Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Beta-cell recovery to counter diabetes

Objective

Globally 8,75M people with T1D rely only on insulin administration to manage the symptoms of their disease. The treatment is complex since it requires injecting insulin (2-4 times/day) and adhering to a restrictive lifestyle (e.g. following a strict diet) reducing patient QoL. Even with insulin, less than 20% of patients achieve their target glucose level, which eventually leads to vascular complications (e.g. stroke, renal disease) reducing life expectancy by 10-15 years.
DiogenX aims to withdraw insulin dependency and cure T1D by regenerating pancreatic beta-cell to allow autonomous insulin release in response to blood glucose levels increases.
We expect to out-license our drug to a pharma company, some of them have already manifested their interest and invested in the capital of DiogenX. This may materialize as soon as clinical proof of principle is demonstrated in humans, which will be reached in 2026 with the proceeds from Series A to be raised in 2023, which is 80% secured.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01

See all projects funded under this call

Coordinator

DIOGENX SAS
Net EU contribution
€ 2 500 000,00
Address
180 AVENUE DU PRADO
13008 Marseille
France
SME
Yes
Region
Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Bouches-du-Rhône
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 5 673 000,00